Austria
Belgium
Estonia
Finland
France
Germany
Greece
Iceland
Ireland
Italy
Liechtenstein
Netherland
Norway
Poland
Portugal
Spain
Sweden
Switzerland
Turkey
United Kingdom
Australia
Fiji
Hong Kong
India
New Zealand
Indonesia
Japan
Malaysia
Philippines
Singapore
Thailand
Brazil
Chile
Colombia
Peru
Mexico
USA
Bahrain
Morocco
Oman
UAE
Saudi Arabia
Tanzania
GLP-1 therapies, Lifestyle medicine and the Future of Workforce Health in the UAE
Prefer us on Google
Obesity and metabolic health are no longer abstract public health issues - they are material workforce risks. In the UAE, high rates of obesity and type 2 diabetes are closely linked to absenteeism, reduced productivity, musculoskeletal conditions, cardiovascular disease and long-term disability. For employers, this translates directly into higher medical costs, lower performance and increased people risk.
Why Employers Should Care
In recent years, GLP-1 therapies, originally developed for diabetes management, have reshaped the conversation around weight management. Evidence demonstrates benefits beyond weight loss, including improvements in blood pressure, blood sugar control, and cholesterol levels, all contributing to a reduced risk of cardiovascular disease. As awareness and availability increase in the UAE, employers are increasingly being asked to consider whether, and how, such treatments should be supported through corporate health plans.
GLP-1 Therapies: A Powerful Tool, Not a Complete Solution
GLP-1 therapies represent an important advance in treating obesity and reducing cardiometabolic risk. However, real world data shows that discontinuation often leads to weight regain and reversal of metabolic improvements, frequently at a faster rate than with behavioural interventions alone. This does not mean the therapies are ineffective. but rather highlights that they are not designed to be used as a short-term, stand-alone solution. Obesity requires long-term management, best delivered through integration with evidence-based behavioural programmes focused on nutrition, physical activity, sleep, and stress management. This approach supports more durable health outcomes and helps reduce overall healthcare costs.
The UAE Context: Prevention First
National health strategy in the UAE places prevention, healthy living and behavioural change at the centre of health system design.
National clinical guidelines for weight management adopt a holistic, multi-component approach built around nutrition, physical activity, and behavioural change, alongside medical and surgical options where clinically indicated.
This direction aligns closely with employer interests. A workforce that eats well, moves more, manages stress and sleeps adequately is more resilient, engaged and productive over the long term.
Lifestyle Medicine as the Anchor
Lifestyle medicine is a scientifically proven, evidence-based approach that focuses on the daily behaviours that determine long-term health outcomes. For UAE employers, it represents the missing link between medical innovation and meaningful workforce impact.
Evidence shows that employees who combine medication with lifestyle change achieve more durable results, lower cardiometabolic risk and better overall wellbeing. By contrast, medication without lifestyle intervention increases cost volatility without delivering sustainable value.
What Leading Employers Are Starting to Do
Progressive UAE employers are moving beyond binary decisions on coverage. Instead, they are linking access to treatment with structured wellbeing support, encouraging integrated care models and measuring success in terms of sustained health outcomes rather than short-term weight loss.
This approach reduces misuse, supports engagement and aligns with national wellbeing objectives.
A Strategic Opportunity for Employers
Workplace health strategies are evolving from cost containment toward value creation. Employers that invest in prevention-focused models benefit from improved engagement, lower long-term risk and stronger employer brand positioning.
Looking Ahead
The future of workforce health in the UAE will not be defined by medication alone. Sustainable outcomes will depend on how organisations integrate prevention, culture, leadership and individual responsibility into people strategies.
GLP-1 therapies have a role to play, but lifestyle medicine must remain the foundation. Employers that get this balance right will be best positioned to support their workforce and manage health-related risk over the long term.
Dr Arti Rampaul, Lifestyle Medicine and Wellbeing Lead Consultant at Howden MEA and one of the leading Lifestyle Medicine practitioners in the UAE says
“While GLP-1 therapies have transformed the management of obesity, they are not sufficient to address the scale of the challenge. We are now living in a global obesity epidemic, with the burden particularly pronounced in the MENA region, where prevalence rates are among the highest worldwide and continue to rise.
Lifestyle Medicine remains a core component of both treatment and prevention, particularly when delivered in the workplace, where it can act as a powerful lever to address the behaviours driving obesity and related chronic conditions. As health outcomes are strongly shaped by the environments in which people live and work, employers have a unique opportunity to implement programmes that support healthier behaviours and enhance the physical and mental wellbeing of their workforce.”
Howden support our clients with a suite of Lifestyle medicine programs that can be specifically designed to cater for your business. If you would like any further information on how we can support the education of your employees in this regard, please do not hesitate to contact me.
